DGAP-News

MOLOGEN is presenting two posters at International Cancer Immunotherapy Conference (news with additional features)

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN is presenting two posters at International Cancer
Immunotherapy Conference (news with additional features)

16.09.2015 / 09:49

---------------------------------------------------------------------

PRESS RELEASE N 14 / 2015 of 09/16/2015

MOLOGEN is presenting two posters at International Cancer Immunotherapy
Conference

Berlin, September 16, 2015 - The biotechnology company MOLOGEN AG is
presenting two posters on the immunotherapies MGN1703 and MGN1601 at the
Inaugural International Cancer Immunotherapy Conference
(CRI-CIMT-EATI-AACR) in New York (September 16 - 19, 2015). The first
poster is outlining detailed pharmacokinetic and pharmacodynamic data from
studies with the immunomodulator MGN1703 in healthy volunteers and cancer
patients. The second poster is featuring immunological data from a study in
renal cancer patients with the cell-based tumor vaccine MGN1601.

Abstract details:
Title: "Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR9
agonist MGN1703 - conclusions by comparison of data from clinical trials
with healthy volunteers and cancer patients"
Poster presentation: September 16, 2015 from 7 p.m. to 9 p.m. in the Empire
Ballroom

Title: "Immune responses against tumor associated antigens are induced by
treatment with the cell-based tumor vaccine MGN1601 in patients with renal
cell carcinoma"
Poster presentation: September 16, 2015 from 7 p.m. to 9 p.m. in the Empire
Ballroom

For more information on the Inaugural International Cancer Immunotherapy
Conference (CRI-CIMT-EATI-AACR) please visit the website
http://www.aacr.org .

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and
strong activation of the immune system. Due to this mechanism of action,
MGN1703 has the potential to be applied to various indications. MGN1703 is
currently being developed for first-line maintenance treatment of
colorectal cancer (pivotal study) and small cell lung cancer (randomized
controlled trial). Furthermore it is also being investigated in a phase I
study in HIV.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.

MOLOGEN AG is listed on the stock exchange and its headquarters are located
in Berlin, Germany. The shares of the company are listed on the Prime